VIP concierge medicine: what it is and is not
Concierge medicine buys access and continuity. It should not buy different clinical standards, and any provider suggesting otherwise deserves scrutiny.
Read articleThe longevity field advances quickly and markets faster than it advances. A physician's guide to reading the difference.
What has genuinely changed
Risk stratification has improved considerably: ApoB and Lp(a) measurement, coronary calcium scoring, continuous glucose monitoring and validated cognitive testing all give clinicians better information than they had a decade ago.
What remains promising but unproven
Senolytic compounds, NAD precursors and various metabolic agents have interesting mechanistic data and limited human outcome evidence. We discuss them honestly and do not sell them as established.
Hospitality can change how care feels. It should never change what care is.
What is marketing
Intravenous vitamin infusions in people with normal levels, unvalidated epigenetic clocks presented as clinical endpoints, and stem cell products offered outside clinical trials. These are expensive and unsupported.
How to evaluate a claim
Ask three questions: was it tested in humans, was the endpoint an outcome or a surrogate marker, and who funded the study. Most longevity marketing fails the first question.
Talk to a clinician
If this article raises a question about your own health, the Averdeno concierge desk can arrange a consultation with the physician best placed to answer it. Written by the Averdeno clinical team and reviewed before publication.
